Manufacturing Setup

Taj Pharma Group has developed a diversified pharmaceutical manufacturing network in India designed to support the production of tablets, capsules, injections, oncology medicines, beta-lactam antibiotics, large-volume parenterals, nutraceuticals, and other specialized pharmaceutical products. Through dedicated manufacturing units and dosage-form-specific facilities, we support large-scale pharmaceutical production while focusing on quality, operational efficiency, product stability, and international market requirements.

Our manufacturing setup includes facilities at Sarigam GIDC, Kalgam Village in Valsad, and Vadgas, Viramgam near Ahmedabad, with individual units dedicated to specific pharmaceutical technologies and product categories. This specialized approach enables us to manage different manufacturing requirements across oral solid dosage forms, sterile products, oncology formulations, beta-lactam products, IV solutions, and nutritional products.

Taj Pharma Manufacturing Plants in India

Our manufacturing infrastructure is organized into specialized production facilities, each designed around particular dosage forms and therapeutic segments. The network includes:

  • Sarigam GIDC Manufacturing Plant – EU GMP and PICs design formulations plant
  • Kalgam Village, Valsad Injections Plant – liquid ampoules, liquid vials, dry injections, and small-volume parenterals
  • Vadgas, Viramgam Block Unit 1 – general liquid injections, dry powders, lyophilized injections, and prefilled syringes
  • Vadgas, Viramgam Block Unit 2 – oncology and cytotoxic formulations
  • Vadgas, Viramgam Unit 3 – beta-lactam products
  • Large Volume Parenterals (LVP) Plant – IV solutions in FFS and Euro Cap bottles
  • Vadgas, Viramgam Block Unit 5 – tablets and capsules with US FDA approval referenced for the unit
  • Vadgas, Viramgam Unit 6 – nutraceuticals and food supplements

This manufacturing structure allows us to separate specialized pharmaceutical operations and develop production capabilities appropriate to different product technologies.

Sarigam GIDC Manufacturing Plant

Our Sarigam GIDC Manufacturing Plant is one of the key facilities within the manufacturing network. The plant is described as an EU GMP and PICs design formulations plant and is equipped to manufacture multiple dosage forms.

The facility supports high-volume production of oral and topical pharmaceutical products, with stated monthly capacities including:

Product CategoryStated Capacity
Tablets120 million/month
Capsules40 million/month
Dry Blended Powders / Granules20 million/month
Effervescent Tablets20 million/month
Oral Jelly60 million/month
Creams / Ointments40 million/month
Oral Sachets3 million/month

The breadth of dosage forms gives the Sarigam facility an important role in supporting diverse pharmaceutical formulation requirements. From conventional tablets and capsules to effervescent tablets, oral jelly, powders, granules, topical creams, ointments, and sachets, the facility is structured for high-capacity formulation manufacturing.

Kalgam Village, Valsad Injections Plant

Our Kalgam Village, Valsad facility is dedicated to injectable pharmaceutical manufacturing, including general small-volume parenteral products and different liquid and dry injectable formats.

The stated production capacities are:

  • Liquid Ampoule Injection: 2.5 lakh units per shift
  • Liquid Vial Injection: 2.5 lakh units per shift
  • Dry Injection: 3.5 lakh units per shift
  • Small Volume Parenterals: 4.5 lakh units per shift

Injectable manufacturing requires controlled production processes and specialized facilities because sterile pharmaceutical products must meet stringent requirements for product quality and safety. The Kalgam facility therefore forms an important part of our overall sterile-product manufacturing capability.

Vadgas, Viramgam – Block Unit 1

Our Vadgas, Viramgam Block Unit 1 is focused on general injectable pharmaceutical products and specialized sterile dosage technologies.

The unit includes capabilities for:

  • General liquid injections
  • General dry powder injections
  • Lyophilized injections
  • Prefilled syringes

Lyophilization, commonly known as freeze-drying, is particularly important for pharmaceutical products that require improved stability in a dry state before reconstitution. Prefilled syringes provide a ready-to-use delivery format and can support convenient administration in appropriate healthcare settings.

By maintaining dedicated capabilities for liquid, dry powder, lyophilized, and prefilled products, the unit supports multiple injectable formulation requirements.

Vadgas, Viramgam – Block Unit 2 Oncology Manufacturing

Our Vadgas, Viramgam Block Unit 2 is dedicated to oncology manufacturing, with a particular focus on cytotoxic pharmaceutical products.

The stated product categories include:

  • Cytotoxic tablets
  • Cytotoxic capsules
  • Cytotoxic liquid injections
  • Cytotoxic dry powder injections
  • Cytotoxic lyophilized injections
  • Suspensions

Oncology manufacturing requires specialized handling and controlled production environments because many cytotoxic medicines possess potent pharmacological activity. A dedicated oncology facility allows manufacturing operations to be organized around the specific requirements associated with these products.

The combination of oral and injectable oncology dosage forms also enables us to support different pharmaceutical delivery requirements within a specialized manufacturing environment.

Vadgas, Viramgam Unit 3 – Beta Lactam Manufacturing Plant

Our Vadgas, Viramgam Unit 3 is dedicated to beta-lactam pharmaceutical manufacturing. Beta-lactam antibiotics represent an important category of antibacterial medicines used in the treatment of bacterial infections.

The facility supports:

  • Beta-lactam tablets
  • Beta-lactam capsules
  • Beta-lactam dry powder injections
  • Beta-lactam dry suspensions

Dedicated manufacturing for beta-lactam products is important because these products require appropriate segregation and controlled manufacturing practices. By allocating a specialized unit to beta-lactam formulations, we maintain a manufacturing structure suited to this important therapeutic category.

The unit contributes to our broader objective of supporting the supply of essential antibiotic formulations for domestic and international pharmaceutical markets.

Large Volume Parenterals (LVP) Manufacturing

Our Large Volume Parenterals (LVP) manufacturing capability is designed for intravenous solutions used in hospital and healthcare settings.

The facility supports the production of IV solutions using PVC bottles, with aseptic filling of aqueous solutions. The manufacturing setup includes two stated bottle formats:

FFS Bottle Production

The Form-Fill-Seal (FFS) bottle line has a stated capacity of:

10 million bottles per day

FFS technology integrates container formation, filling, and sealing into a controlled manufacturing process. This technology is particularly relevant to high-volume pharmaceutical packaging requirements.

Euro Cap Bottle Production

The Euro Cap bottle line has a stated capacity of:

5 million bottles per day

Together, the two formats provide substantial stated production capacity for large-volume intravenous solutions.

Vadgas, Viramgam – Block Unit 5

Our Vadgas, Viramgam Block Unit 5 is focused on oral solid dosage manufacturing, specifically tablets and capsules.

The source information identifies US FDA approval in connection with the tablet and capsule manufacturing capability of this unit. The facility is therefore positioned to support pharmaceutical products intended to meet stringent international manufacturing expectations.

Tablets and capsules remain among the most widely used pharmaceutical dosage forms because they provide practical administration, efficient manufacturing, and flexibility across numerous therapeutic categories.

Vadgas, Viramgam Unit 6 – Nutraceuticals and Food Supplements

Our Vadgas, Viramgam Unit 6 is dedicated to nutraceuticals and food supplements.

This manufacturing capability complements our pharmaceutical production infrastructure by supporting products intended for nutritional and wellness applications. The dedicated unit enables us to address the expanding requirement for nutritional formulations alongside conventional pharmaceutical products.

Integrated Pharmaceutical Manufacturing Capabilities

The strength of our manufacturing setup lies in the specialization of individual facilities. Instead of relying on a single manufacturing technology, our network encompasses multiple dosage forms and pharmaceutical segments.

Our manufacturing capabilities span:

Oral Solid Dosages: Tablets and capsules, including specialized beta-lactam and oncology products.

Injectables: Liquid ampoules, liquid vials, dry powder injections, lyophilized injections, and prefilled syringes.

Parenterals: Small-volume and large-volume parenteral products.

Oncology: Cytotoxic tablets, capsules, injections, and other specialized formulations.

Antibiotics: Dedicated beta-lactam tablets, capsules, dry injections, and dry suspensions.

Topical Products: Creams and ointments.

Alternative Oral Dosage Forms: Effervescent tablets, oral jelly, dry blended powders, granules, and oral sachets.

Nutraceuticals: Food supplements and nutritional products.

This diversity allows us to address different product-development and commercial manufacturing requirements across multiple pharmaceutical categories.

Quality-Oriented Manufacturing Infrastructure

Our manufacturing facilities are structured around specialized production requirements and international pharmaceutical manufacturing expectations. The source information references EU GMP, PICs, and US FDA-related manufacturing capabilities across specific facilities.

Quality-oriented manufacturing requires consistent control over raw materials, manufacturing processes, environmental conditions, equipment, packaging operations, documentation, and finished-product testing. Specialized facilities further support appropriate segregation and handling of products requiring dedicated manufacturing arrangements.

Our objective is to combine manufacturing scale with controlled pharmaceutical production processes, allowing the facilities to support both high-volume conventional dosage forms and technically specialized products.

Manufacturing Capacity and Global Pharmaceutical Supply

The stated capacities across the manufacturing network demonstrate a substantial production infrastructure. The Sarigam facility alone has stated monthly capacities of 120 million tablets and 40 million capsules, in addition to multiple other dosage forms.

The injectable facilities provide substantial shift-based production capabilities, while the LVP manufacturing setup is designed around very high daily bottle production capacity. Dedicated oncology and beta-lactam facilities further expand the range of products that can be manufactured within the overall network.

This combination of capacity, dosage-form diversity, specialized manufacturing units, and international quality references provides a foundation for serving pharmaceutical requirements across different markets.

Our manufacturing setup at Taj Pharma Group represents a diversified pharmaceutical production network covering oral solids, sterile injections, oncology medicines, beta-lactam antibiotics, large-volume parenterals, topical products, alternative dosage forms, nutraceuticals, and food supplements.

From the high-capacity Sarigam GIDC Manufacturing Plant to the injectable facility at Kalgam Village, Valsad, and the specialized manufacturing units at Vadgas, Viramgam near Ahmedabad, each facility has a defined role within the broader manufacturing infrastructure.

With dedicated capabilities for tablets, capsules, injections, dry powders, lyophilized products, prefilled syringes, oncology formulations, beta-lactam antibiotics, IV solutions, creams, ointments, oral jelly, effervescent tablets, sachets, nutraceuticals, and food supplements, our manufacturing network is designed to support a broad pharmaceutical portfolio.

The combination of specialized facilities, large stated production capacities, and international quality-standard references establishes Taj Pharma Group as a manufacturing platform focused on scalable pharmaceutical production and global healthcare supply.

Frequently Asked Questions

What is the manufacturing capacity of the Sarigam GIDC Plant?

The stated capacity includes 120 million tablets per month, 40 million capsules per month, 20 million dry blended powders/granules per month, 20 million effervescent tablets per month, 60 million oral jelly units per month, 40 million cream/ointment units per month, and 3 million oral sachets per month.

What products are manufactured at the Kalgam Village plant?

The Kalgam Village, Valsad facility is described as an injections plant producing liquid ampoule injections, liquid vial injections, dry injections, and small-volume parenterals.

What is manufactured at Vadgas Viramgam Unit 2?

Unit 2 is dedicated to oncology and cytotoxic products, including tablets, capsules, liquid injections, dry powder injections, lyophilized injections, and suspensions.

What is manufactured at Vadgas Viramgam Unit 3?

Unit 3 specializes in beta-lactam products, including tablets, capsules, dry powder injections, and dry suspensions.

What is the LVP manufacturing capacity?

The stated LVP capacity is 10 million FFS bottles per day and 5 million Euro Cap bottles per day.

What is manufactured at Vadgas Unit 6?

Vadgas Unit 6 is dedicated to nutraceuticals and food supplements.

What makes the Taj Pharma manufacturing network different?

The manufacturing network combines high-volume pharmaceutical production with specialized facilities for injections, oncology, beta-lactam antibiotics, LVP solutions, oral solid dosages, nutraceuticals, and other dosage forms. This specialized structure enables different product categories to be manufactured through dedicated production capabilities.